LungLife AI, INC — Director's Dealing 2021

Jul 8, 2021

National Storage Mechanism | Additional information

RNS Number : 5436E

LungLife AI, INC

08 July 2021

LungLife AI, Inc. 

("LungLife" or the "Company")  

Director/PDMR Notification

LungLife  (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each ("Common Shares") undertaken by directors.

The transactions were made in connection with the placing of new Common Shares in the capital of the Company as part of the Company's admission to trading on AIM.

Roy Davis, Non-Executive Chair, has today purchased 14,204 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Davis now holds 14,204 Common Shares, representing approximately 0.06% of the outstanding share capital of the Company.

In addition, Andrew Boteler, Non-Executive Director, has today purchased 5,681 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Boteler now holds 5,681 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1)    Roy Davis

2)    Andrew Boteler

2

Reason for the notification

a)

Position/status

1)   Non-Executive Chairman

2)   Non-Executive Director

b)

Initial notification /Amendment

1)    Initial notification

2)    Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

LungLife AI, Inc.

b)

LEI

549300VBVDIF0Y3OVI38

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of $0.0001 each in the capital of the Company

ISIN: USU5500L1045

b)

Nature of the transaction

Purchase of Common Shares

c)

Price(s) and volume(s)

Price	No. of shares
1) 176.0p 2) 176.0p	1) 14,204 2) 5,681

d)

Aggregated information

- Aggregated  volume

- Price

N/a - single transaction

e)

Date of the transaction

8 July 2021

f)

Place of the transaction

London Stock Exchange, AIM

- Ends -

For further information please contact:

LungLife AI, Inc.		www.lunglifeai.com
Paul Pagano, CEO		Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Broker)		Tel: +44 (0)20 7597 5970
Daniel Adams / Virginia Bull / Cameron MacRitchie
Walbrook PR Limited	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings		Mob: 07980 541 893 / 07407 804 654

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKOBNBBKBNOK